Form D · Biotechnology
Cotinga Pharmaceuticals Inc.
London, A6 · CIK 0001585808
Offering snapshot reported May 15, 2018 · SEC filing
- Reported sold
- $1.58M Offering amount: $1.58M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 3, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2018 | Initial | $1,580,439 | No comparison | 6 | SEC filing |
| May 24, 2017 | Amendment | $0 | $0vs Jun 10, 2016 | 2 | SEC filing |
| Jun 10, 2016 | Amendment | $0 | $0vs May 8, 2015 | 2 | SEC filing |
| May 27, 2016 | Initial | $0 | No comparison | 1 | SEC filing |
| May 27, 2016 | Initial | $1,100,000 | No comparison | 1 | SEC filing |
| May 27, 2016 | Initial | $0 | No comparison | 3 | SEC filing |
| Aug 18, 2015 | Initial | $13,796 | No comparison | 1 | SEC filing |
| May 8, 2015 | Amendment | $0 | -$285,000vs May 6, 2014 | 2 | SEC filing |
| Sep 25, 2014 | Amendment | $45,758 | $0vs Sep 4, 2013 | 1 | SEC filing |
| Sep 25, 2014 | Amendment | $0 | $0vs Sep 9, 2013 | 1 | SEC filing |
| May 6, 2014 | Initial | $285,000 | No comparison | 2 | SEC filing |
| Sep 9, 2013 | Initial | $0 | No comparison | 1 | SEC filing |
| Sep 4, 2013 | Initial | $45,758 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $168K
- Finders' fees
- $0
- Form D file number
- 021-312440
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Roth Capital Partners LLC | 15407 |
Source: Form D, filed May 15, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas S Alexander | Director |
| Bharatt Chowrira | Director |
| Wayne R Danter | Director, Executive |
| John C Drake | Director |
| Kathleen Ferguson | Director |
| Gene Kelly | Executive |
| Bruno Maruzzo | Director |
| Brent Norton | Director |
| David Sanderson | Director |
| Alison Silva | Director, Executive |
| Murray Wallace | Director |
| Thomas Wellner | Director |
| John Yoo | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Suite 230 B, The Mogenson Centre 100 Collip Circle
London, A6, N6G 4X8
London, A6, N6G 4X8